CD274 and neoplasm: Among GEA patients, the PD-L1 combined positivity score (CPS), consisting of immunohistochemistry-detected protein in at least 1% of cells in the tumor or surrounding stroma, is often used for candidate selection in pembrolizumab-related trials.